Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis

Objectives: To compare receptor activator of NF-κB ligand (RANKL) production in the synovial tissue from patients with active rheumatoid arthritis (RA), inactive RA, spondyloarthropathies (SpA), osteoarthritis, and from normal subjects. In addition, to establish the cell lineages expressing RANKL in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the rheumatic diseases 2002-12, Vol.61 (12), p.1047-1054
Hauptverfasser: Crotti, T N, Smith, M D, Weedon, H, Ahern, M J, Findlay, D M, Kraan, M, Tak, P P, Haynes, D R
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1054
container_issue 12
container_start_page 1047
container_title Annals of the rheumatic diseases
container_volume 61
creator Crotti, T N
Smith, M D
Weedon, H
Ahern, M J
Findlay, D M
Kraan, M
Tak, P P
Haynes, D R
description Objectives: To compare receptor activator of NF-κB ligand (RANKL) production in the synovial tissue from patients with active rheumatoid arthritis (RA), inactive RA, spondyloarthropathies (SpA), osteoarthritis, and from normal subjects. In addition, to establish the cell lineages expressing RANKL in these tissues. Methods: Immunohistological analysis of frozen synovial tissue biopsy specimens was performed using a monoclonal antibody (mAb) to detect RANKL. Sections were evaluated by computer assisted image analysis and semiquantitative analysis to compare RANKL expression between groups. Dual and sequential labelling with mAb RANKL and cell lineage specific monoclonal antibodies were used to determine the types of cells expressing RANKL. Results: Higher levels of RANKL were expressed in tissues from patients with active RA and SpA than in tissues from patients with inactive RA, osteoarthritis, and from normal subjects. RANKL protein was associated with CD3 antigen-positive lymphocytes and some macrophages. RANKL was predominantly associated with activated, memory T cells (CD45Ro positive cells) in patients with active RA and spondyloarthropathy (SpA). Conclusions: The highest levels of RANKL were detected in patients with RA with active synovitis and in some patients with SpA. An increase in RANKL in the inflamed joint of patients with RA, produced by infiltrating activated T cells and macrophages, is likely to be an important cause of joint erosions in RA.
doi_str_mv 10.1136/ard.61.12.1047
format Article
fullrecord <record><control><sourceid>istex_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1753975</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ark_67375_NVC_P3CT554J_3</sourcerecordid><originalsourceid>FETCH-LOGICAL-b310t-d1bbbcf6bafcde2145ab9c85141ed3d6f114e6d1994ddd6c139fc8a4cc872f0b3</originalsourceid><addsrcrecordid>eNpdks2O0zAQgC0EYkvhytkXJFbaFE_sOAkHpKVi-asKWi1cLcd2tl6SONhu2b4aD8Gdt8Ftl-XnYNme-eYbyxqEHgOZAVD-THo94zCDfAaElXfQBBivspxwchdNCCE0YzUvj9CDEK7SlVRQ3UdHkLO8LiidoJ_nRpkxOo-linYjd6flWfbj-0vc2Us5aPz0_HT5fnGMzfXoTQjWDdgOOGwHt7Gyw9GGsDa49a7Ho4zWDDHgbzausF-ZdZ-EVmPp48rbhJ7gMLpBbzu3D7lUsdqeYBeicX9Bu7574-B8n5r8Fj_HwfT261oO0cYU25g9-l9Adttgw0N0r5VdMI9u9in6dPbqYv4mW3x4_XZ-usgaCiRmGpqmUS1vZKu0yYEVsqlVVQADo6nmLQAzXENdM601V0DrVlWSKVWVeUsaOkUvDt5x3fRGq_ROLzsxettLvxVOWvFvZrArcek2AsqC1mlN0ZMbgQxKdq2Xg7LhVgCMkDqHPHHZgbPpt65v89J_EbykZSGWn-fiI51fFAV7J2jijw9801_9sRGxm5tUpQUHAbnYzQ39Befgvcs</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Crotti, T N ; Smith, M D ; Weedon, H ; Ahern, M J ; Findlay, D M ; Kraan, M ; Tak, P P ; Haynes, D R</creator><creatorcontrib>Crotti, T N ; Smith, M D ; Weedon, H ; Ahern, M J ; Findlay, D M ; Kraan, M ; Tak, P P ; Haynes, D R</creatorcontrib><description>Objectives: To compare receptor activator of NF-κB ligand (RANKL) production in the synovial tissue from patients with active rheumatoid arthritis (RA), inactive RA, spondyloarthropathies (SpA), osteoarthritis, and from normal subjects. In addition, to establish the cell lineages expressing RANKL in these tissues. Methods: Immunohistological analysis of frozen synovial tissue biopsy specimens was performed using a monoclonal antibody (mAb) to detect RANKL. Sections were evaluated by computer assisted image analysis and semiquantitative analysis to compare RANKL expression between groups. Dual and sequential labelling with mAb RANKL and cell lineage specific monoclonal antibodies were used to determine the types of cells expressing RANKL. Results: Higher levels of RANKL were expressed in tissues from patients with active RA and SpA than in tissues from patients with inactive RA, osteoarthritis, and from normal subjects. RANKL protein was associated with CD3 antigen-positive lymphocytes and some macrophages. RANKL was predominantly associated with activated, memory T cells (CD45Ro positive cells) in patients with active RA and spondyloarthropathy (SpA). Conclusions: The highest levels of RANKL were detected in patients with RA with active synovitis and in some patients with SpA. An increase in RANKL in the inflamed joint of patients with RA, produced by infiltrating activated T cells and macrophages, is likely to be an important cause of joint erosions in RA.</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/ard.61.12.1047</identifier><identifier>PMID: 12429533</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><subject>3-amino-9-ethylcarbazole ; AEC ; Biological and medical sciences ; bone ; DIA ; digital image analysis ; Diseases of the osteoarticular system ; Extended Report ; fibroblast-like synoviocytes ; FLS ; horseradish peroxidase ; HRP ; immunohistochemistry ; Inflammatory joint diseases ; integrated optical density ; interleukin ; IOD ; mAb ; mean optical density ; Medical sciences ; MOD ; monoclonal antibody ; OPG ; Osteoarthritis ; osteoprotegerin ; RANK ; RANKL ; receptor activator NF-κB ligand ; receptor activator of NF-κB ; receptor activator of NF-κB ligand ; rheumatoid arthritis ; semiquantitative assessment ; SpA ; spondyloarthropathies ; spondyloarthropathy ; SQA ; TNF ; tumour necrosis factor</subject><ispartof>Annals of the rheumatic diseases, 2002-12, Vol.61 (12), p.1047-1054</ispartof><rights>Copyright 2002 by Annals of the Rheumatic Diseases</rights><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1753975/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1753975/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,315,728,781,785,886,27928,27929,53795,53797</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=14009212$$DView record in Pascal Francis$$Hfree_for_read</backlink></links><search><creatorcontrib>Crotti, T N</creatorcontrib><creatorcontrib>Smith, M D</creatorcontrib><creatorcontrib>Weedon, H</creatorcontrib><creatorcontrib>Ahern, M J</creatorcontrib><creatorcontrib>Findlay, D M</creatorcontrib><creatorcontrib>Kraan, M</creatorcontrib><creatorcontrib>Tak, P P</creatorcontrib><creatorcontrib>Haynes, D R</creatorcontrib><title>Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis</title><title>Annals of the rheumatic diseases</title><addtitle>Ann Rheum Dis</addtitle><description>Objectives: To compare receptor activator of NF-κB ligand (RANKL) production in the synovial tissue from patients with active rheumatoid arthritis (RA), inactive RA, spondyloarthropathies (SpA), osteoarthritis, and from normal subjects. In addition, to establish the cell lineages expressing RANKL in these tissues. Methods: Immunohistological analysis of frozen synovial tissue biopsy specimens was performed using a monoclonal antibody (mAb) to detect RANKL. Sections were evaluated by computer assisted image analysis and semiquantitative analysis to compare RANKL expression between groups. Dual and sequential labelling with mAb RANKL and cell lineage specific monoclonal antibodies were used to determine the types of cells expressing RANKL. Results: Higher levels of RANKL were expressed in tissues from patients with active RA and SpA than in tissues from patients with inactive RA, osteoarthritis, and from normal subjects. RANKL protein was associated with CD3 antigen-positive lymphocytes and some macrophages. RANKL was predominantly associated with activated, memory T cells (CD45Ro positive cells) in patients with active RA and spondyloarthropathy (SpA). Conclusions: The highest levels of RANKL were detected in patients with RA with active synovitis and in some patients with SpA. An increase in RANKL in the inflamed joint of patients with RA, produced by infiltrating activated T cells and macrophages, is likely to be an important cause of joint erosions in RA.</description><subject>3-amino-9-ethylcarbazole</subject><subject>AEC</subject><subject>Biological and medical sciences</subject><subject>bone</subject><subject>DIA</subject><subject>digital image analysis</subject><subject>Diseases of the osteoarticular system</subject><subject>Extended Report</subject><subject>fibroblast-like synoviocytes</subject><subject>FLS</subject><subject>horseradish peroxidase</subject><subject>HRP</subject><subject>immunohistochemistry</subject><subject>Inflammatory joint diseases</subject><subject>integrated optical density</subject><subject>interleukin</subject><subject>IOD</subject><subject>mAb</subject><subject>mean optical density</subject><subject>Medical sciences</subject><subject>MOD</subject><subject>monoclonal antibody</subject><subject>OPG</subject><subject>Osteoarthritis</subject><subject>osteoprotegerin</subject><subject>RANK</subject><subject>RANKL</subject><subject>receptor activator NF-κB ligand</subject><subject>receptor activator of NF-κB</subject><subject>receptor activator of NF-κB ligand</subject><subject>rheumatoid arthritis</subject><subject>semiquantitative assessment</subject><subject>SpA</subject><subject>spondyloarthropathies</subject><subject>spondyloarthropathy</subject><subject>SQA</subject><subject>TNF</subject><subject>tumour necrosis factor</subject><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><recordid>eNpdks2O0zAQgC0EYkvhytkXJFbaFE_sOAkHpKVi-asKWi1cLcd2tl6SONhu2b4aD8Gdt8Ftl-XnYNme-eYbyxqEHgOZAVD-THo94zCDfAaElXfQBBivspxwchdNCCE0YzUvj9CDEK7SlVRQ3UdHkLO8LiidoJ_nRpkxOo-linYjd6flWfbj-0vc2Us5aPz0_HT5fnGMzfXoTQjWDdgOOGwHt7Gyw9GGsDa49a7Ho4zWDDHgbzausF-ZdZ-EVmPp48rbhJ7gMLpBbzu3D7lUsdqeYBeicX9Bu7574-B8n5r8Fj_HwfT261oO0cYU25g9-l9Adttgw0N0r5VdMI9u9in6dPbqYv4mW3x4_XZ-usgaCiRmGpqmUS1vZKu0yYEVsqlVVQADo6nmLQAzXENdM601V0DrVlWSKVWVeUsaOkUvDt5x3fRGq_ROLzsxettLvxVOWvFvZrArcek2AsqC1mlN0ZMbgQxKdq2Xg7LhVgCMkDqHPHHZgbPpt65v89J_EbykZSGWn-fiI51fFAV7J2jijw9801_9sRGxm5tUpQUHAbnYzQ39Befgvcs</recordid><startdate>20021201</startdate><enddate>20021201</enddate><creator>Crotti, T N</creator><creator>Smith, M D</creator><creator>Weedon, H</creator><creator>Ahern, M J</creator><creator>Findlay, D M</creator><creator>Kraan, M</creator><creator>Tak, P P</creator><creator>Haynes, D R</creator><general>BMJ Publishing Group Ltd and European League Against Rheumatism</general><general>BMJ</general><scope>BSCLL</scope><scope>IQODW</scope><scope>5PM</scope></search><sort><creationdate>20021201</creationdate><title>Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis</title><author>Crotti, T N ; Smith, M D ; Weedon, H ; Ahern, M J ; Findlay, D M ; Kraan, M ; Tak, P P ; Haynes, D R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b310t-d1bbbcf6bafcde2145ab9c85141ed3d6f114e6d1994ddd6c139fc8a4cc872f0b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>3-amino-9-ethylcarbazole</topic><topic>AEC</topic><topic>Biological and medical sciences</topic><topic>bone</topic><topic>DIA</topic><topic>digital image analysis</topic><topic>Diseases of the osteoarticular system</topic><topic>Extended Report</topic><topic>fibroblast-like synoviocytes</topic><topic>FLS</topic><topic>horseradish peroxidase</topic><topic>HRP</topic><topic>immunohistochemistry</topic><topic>Inflammatory joint diseases</topic><topic>integrated optical density</topic><topic>interleukin</topic><topic>IOD</topic><topic>mAb</topic><topic>mean optical density</topic><topic>Medical sciences</topic><topic>MOD</topic><topic>monoclonal antibody</topic><topic>OPG</topic><topic>Osteoarthritis</topic><topic>osteoprotegerin</topic><topic>RANK</topic><topic>RANKL</topic><topic>receptor activator NF-κB ligand</topic><topic>receptor activator of NF-κB</topic><topic>receptor activator of NF-κB ligand</topic><topic>rheumatoid arthritis</topic><topic>semiquantitative assessment</topic><topic>SpA</topic><topic>spondyloarthropathies</topic><topic>spondyloarthropathy</topic><topic>SQA</topic><topic>TNF</topic><topic>tumour necrosis factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Crotti, T N</creatorcontrib><creatorcontrib>Smith, M D</creatorcontrib><creatorcontrib>Weedon, H</creatorcontrib><creatorcontrib>Ahern, M J</creatorcontrib><creatorcontrib>Findlay, D M</creatorcontrib><creatorcontrib>Kraan, M</creatorcontrib><creatorcontrib>Tak, P P</creatorcontrib><creatorcontrib>Haynes, D R</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Crotti, T N</au><au>Smith, M D</au><au>Weedon, H</au><au>Ahern, M J</au><au>Findlay, D M</au><au>Kraan, M</au><au>Tak, P P</au><au>Haynes, D R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis</atitle><jtitle>Annals of the rheumatic diseases</jtitle><addtitle>Ann Rheum Dis</addtitle><date>2002-12-01</date><risdate>2002</risdate><volume>61</volume><issue>12</issue><spage>1047</spage><epage>1054</epage><pages>1047-1054</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>Objectives: To compare receptor activator of NF-κB ligand (RANKL) production in the synovial tissue from patients with active rheumatoid arthritis (RA), inactive RA, spondyloarthropathies (SpA), osteoarthritis, and from normal subjects. In addition, to establish the cell lineages expressing RANKL in these tissues. Methods: Immunohistological analysis of frozen synovial tissue biopsy specimens was performed using a monoclonal antibody (mAb) to detect RANKL. Sections were evaluated by computer assisted image analysis and semiquantitative analysis to compare RANKL expression between groups. Dual and sequential labelling with mAb RANKL and cell lineage specific monoclonal antibodies were used to determine the types of cells expressing RANKL. Results: Higher levels of RANKL were expressed in tissues from patients with active RA and SpA than in tissues from patients with inactive RA, osteoarthritis, and from normal subjects. RANKL protein was associated with CD3 antigen-positive lymphocytes and some macrophages. RANKL was predominantly associated with activated, memory T cells (CD45Ro positive cells) in patients with active RA and spondyloarthropathy (SpA). Conclusions: The highest levels of RANKL were detected in patients with RA with active synovitis and in some patients with SpA. An increase in RANKL in the inflamed joint of patients with RA, produced by infiltrating activated T cells and macrophages, is likely to be an important cause of joint erosions in RA.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and European League Against Rheumatism</pub><pmid>12429533</pmid><doi>10.1136/ard.61.12.1047</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0003-4967
ispartof Annals of the rheumatic diseases, 2002-12, Vol.61 (12), p.1047-1054
issn 0003-4967
1468-2060
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1753975
source EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection
subjects 3-amino-9-ethylcarbazole
AEC
Biological and medical sciences
bone
DIA
digital image analysis
Diseases of the osteoarticular system
Extended Report
fibroblast-like synoviocytes
FLS
horseradish peroxidase
HRP
immunohistochemistry
Inflammatory joint diseases
integrated optical density
interleukin
IOD
mAb
mean optical density
Medical sciences
MOD
monoclonal antibody
OPG
Osteoarthritis
osteoprotegerin
RANK
RANKL
receptor activator NF-κB ligand
receptor activator of NF-κB
receptor activator of NF-κB ligand
rheumatoid arthritis
semiquantitative assessment
SpA
spondyloarthropathies
spondyloarthropathy
SQA
TNF
tumour necrosis factor
title Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T09%3A34%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-istex_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Receptor%20activator%20NF-%CE%BAB%20ligand%20(RANKL)%20expression%20in%20synovial%20tissue%20from%20patients%20with%20rheumatoid%20arthritis,%20spondyloarthropathy,%20osteoarthritis,%20and%20from%20normal%20patients:%20semiquantitative%20and%20quantitative%20analysis&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Crotti,%20T%20N&rft.date=2002-12-01&rft.volume=61&rft.issue=12&rft.spage=1047&rft.epage=1054&rft.pages=1047-1054&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/ard.61.12.1047&rft_dat=%3Cistex_pubme%3Eark_67375_NVC_P3CT554J_3%3C/istex_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/12429533&rfr_iscdi=true